For maximum effectiveness, begin treatment at first sign of headache. Open one unit dose dispenser by tearing off the perforated end and dispensing entire contents under the tongue. Important : Hold in place under the tongue for at least 60 seconds; then swallow. Repeat after 5 minutes using a second unit dose dispenser, hold the second dose under the tongue for at least 60 seconds before swallowing. Additional me...
www.LipiGesic.comWhat is a Migraine?
Migraines are classified as “benign headaches” because they are not caused by an underlying medical condition such as a tumor, aneurysm or a similar medical disorder. But, migraine is far from “benign” in terms of its impact on the individual and those around them.
The pain of a migraine headache is often described as an intense pulsing, throbbing and sometimes disabling pain, which may be limited to one side of the head. It may be accompanied by sensitivity to light and sound, nausea and vomiting.
There are two major types of migraine headache: classic and common. Classic migraines are often signaled by “aura,” a visual sensory illusion, such as jagged bands of light obscuring vision, or shimmering lights around the edges of objects, before the actual pain begins. Only about 20 percent of sufferers experience aura. Common migraines occur without aura.
Migraine headaches may result from dietary, environmental and lifestyle triggers. Most migraines are not caused by a single identifiable source, and a person's response to a trigger varies from occurrence to occurrence.
LipiGesic-M is a non-prescription sublingual (under-the-tongue) formulation of natural ingredients used in the early stages of onset to relieve the pain and reduce the associated symptoms of migraine – nausea, vomiting, and sensitivity to light and sound.
In a double-blind placebo controlled study, 64% of headaches resolved with no pain or only mild pain, within 2 hours after LipiGesic-M was taken. (In most cases, relief was experienced prior to the 2-hour- study benchmark.)
LipiGesic-M is highly effective for the treatment of migraine pain and may cost up to 75% less than the leading prescription migraine medications. Available over-the-counter, LipiGesic-M is the best, first-line defense in the treatment of migraine. Each dose of LipiGesic-M is pre-measured; it is easy to use and easy to transport.
LipiGesic-M is extremely safe. It can be used by virtually all migraine sufferers.
If pregnant or breast- feeding, ask a health care professional before use.
Also, you should talk to you doctor before using if you have: the worst headache of your life; fever and stiff neck; daily headaches; a headache that is different from your usual migraine; headache that begins after or is caused by head injury, exertion, coughing or bending; experience your first headaches after the age of 50; any continuing medical conditions; migraine headache pain that worsens or continues for more than 48 hours; new or unexpected symptoms.
If a significant allergic reaction occurs, stop using the product and seek immediate medical help.
Please keep this and all drugs out of the reach of children.
Few side effects have been reported, but may include: body aches, stomach cramps, vomiting, heartburn, nausea and oral numbness.
There are no known drug interactions with LipiGesic-M. However, you should speak with your doctor or pharmacist if you are taking other medications.
For maximum effectiveness, begin treatment at first sign of headache.
Important: Hold in place under the tongue for at least 60 seconds; then swallow.
Feverfew (3X), Ginger (2X)
N.F. Grade Olive Oil, Silicon Dioxide, Peppermint Flavor
For relief of migraine and associated symptoms.
Use only if dispenser is intact.
LipiGesic™-M is fast.
Medications absorbed through the digestive tract generally take up to an hour just to start working, and absorption is highly variable. With the sublingual unit dose system, LipiGesic-M achieves consistent absorption that begins within minutes.
LipiGesic-M is powerful.
LipiGesic-M's patent-pending formulation, has been shown to be a safe and effective first-line treatment when used at the onset of migraine.* LipiGesic-M is non-habit forming and not associated with rebound headache.
The active ingredients, Feverfew and Ginger, have had a long history of use and have an excellent safety profile. They have been combined to provide a unique and powerful defense against migraine pain and associated symptoms.
After 2 hours, 64% of migraines treated with LipiGesic-M resulted in little or no pain.*
LipiGesic™-M is a patent - pending medication designed to provide fast and effective relief from the pain and associated symptoms of migraine. Unlike typical pills and capsules, LipiGesic-M starts to work almost immediately
Active ingredients are often destroyed when first passing through the stomach or liver – before they have a chance to reach their intended target. Sublingual (under the tongue) administration prevents this “first pass” destruction by delivering the product directly to the bloodstream through the rich network of blood vessels under the tongue. LipiGesic-M's full- strength active ingredients reach the bloodstream faster and more effectively.
The unit dose system is a patent-pending delivery system developed by PuraMed BioScience, and includes the dispenser as well as specific formula enhancements used to improve the sublingual absorption of LipiGesic-M. The unit dose system is an important part of PuraMed's effort to create products that work faster, are more effective and offer better safety profiles than similar products administered by traditional means.
PuraMed™
BIOSCIENCE
Manufactured for
PuraMed BioScience, Inc. P.O. Box 677, 1326 Schofield Ave. Schofield, WI 54476
For more information:
www.LipiGesic.com
877-851-2190
info@LipiGesic.com
© PuraMed BioScience 2011 002-1011-1
Principal Display Panel – Box Label
PATENT PENDING HOMEOPATHIC DRUG
LipiGesic™ M
Fast Relief for Migraine Pain
Net Contents 24 ml (.8115 ounces) Unit Dose Dispeners
Principal Display Panel – Dose Unit Label
LipiGesic M
Migraine
Headache Pain Reliever
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 34331-202-06 | 2025-01-06 | C162847 | 48780-1 | 97449f38-bf12-f6ea-e053-dbdaa90aa703 | db04a14c-b6b7-4f81-be84-55052e6ed70a |
| 34331-202-06 | 2019-11-13 | C162847 | 48780-1 | 97449f38-bf12-f6ea-e053-dbdaa90aa703 | db04a14c-b6b7-4f81-be84-55052e6ed70a |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| feverfew | ACTIVE INGREDIENT | Z64FK7P217 | 2 | |
| Ginger | ACTIVE INGREDIENT | C5529G5JPQ | 2 | |
| feverfew | ACTIVE MOIETY | Z64FK7P217 | 2 | |
| Ginger | ACTIVE MOIETY | C5529G5JPQ | 2 | |
| Olive Oil | INACTIVE INGREDIENT | 6UYK2W1W1E | 2 | |
| Silicon Dioxide | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 34331-202 | 34331-202-06 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| feverfew | Z64FK7P217 | ACTIB |
| Ginger | C5529G5JPQ | ACTIB |
| Olive Oil | 6UYK2W1W1E | IACT |
| Silicon Dioxide | ETJ7Z6XBU4 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / DENTAL | 19 %w/w | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 170 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| Olive Oil | OLIVE OIL | 6UYK2W1W1E | SOLUTION / ORAL | 425 mg/1ml | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| Olive Oil | OLIVE OIL | 6UYK2W1W1E | SOAP / TOPICAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SYSTEM / TRANSDERMAL | 35 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| Olive Oil | OLIVE OIL | 6UYK2W1W1E | SOLUTION / TOPICAL | 0.6 %w/w | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / SUBLINGUAL | 10 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, LIQUID FILLED / ORAL | 106 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SOLUTION / ORAL | 336 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 69 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SUSPENSION / ORAL | 2553 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TAMPON / VAGINAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SOLUTION / ORAL | 1.8 mg/120ml | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE / ORAL | 254 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, DELAYED RELEASE / ORAL | 40 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / TOPICAL | 6 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SOLUTION / ORAL | 280 mg | ||
| Olive Oil | OLIVE OIL | 6UYK2W1W1E | CAPSULE / ORAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FOR SUSPENSION / ORAL | 220 mg | ||
| Olive Oil | OLIVE OIL | 6UYK2W1W1E | LOTION / TOPICAL | 32468 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION / ORAL | 400 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2b105ec3-4082-dc4d-e063-6394a90a340d | db04a14c-b6b7-4f81-be84-55052e6ed70a | 2025-01-06 | Warnings, Adverse reactions | db04a14c-b6b7-4f81-be84-55052e6ed70a |
Adverse event summaries are temporarily unavailable. Other product information remains available.